A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Nature medicine – Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo Audrey SM, Ariyaratne PN,Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JWJ, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H,Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DSW, Soda M, Isobe K, Nöthen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Yasushi;Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST (2012)
18 (4); 521-8